|1.||Atadja, Peter: 21 articles (07/2009 - 08/2003)|
|2.||Bhalla, Kapil: 7 articles (10/2008 - 08/2003)|
|3.||Bali, Purva: 5 articles (09/2005 - 08/2003)|
|4.||Workman, Paul: 4 articles (02/2012 - 08/2006)|
|5.||Remiszewski, Stacy: 4 articles (04/2004 - 10/2003)|
|6.||Fiskus, Warren: 3 articles (10/2008 - 08/2004)|
|7.||Qian, David Z: 3 articles (01/2007 - 09/2004)|
|8.||Pili, Roberto: 3 articles (01/2007 - 09/2004)|
|9.||Moscinski, Lynn: 3 articles (08/2004 - 08/2003)|
|10.||Tao, Jianguo: 3 articles (08/2004 - 08/2003)|
11/01/2003 - "Based, in part, on these properties, NVP-LAQ824 is currently undergoing human clinical trials as a novel anti-cancer agent."
04/01/2008 - "Treatment with LAQ824 resulted in altered phospholipid metabolism and compromised tumor bioenergetics. "
08/01/2007 - "Fractioned irradiation and LAQ824 delayed tumor growth by 19 days versus 7 and 4 days for treatment with LAQ824 and radiation alone. "
08/01/2006 - "These data provide insight into the mechanism underlying the selective induction of apoptosis by LAQ824 in cancer cells."
08/01/2006 - "Activation of mitochondrial pathway is crucial for tumor selective induction of apoptosis by LAQ824."
|2.||Breast Neoplasms (Breast Cancer)
10/01/2003 - "Present studies demonstrate that exposure to a novel hydroxamic acid analogue histone deacetylase inhibitor, LAQ824, induced p21WAF1 and p27KIP1 and caused growth arrest and apoptosis of human breast cancer SKBR-3 and BT-474 cells that possess amplification and overexpression of Her-2/neu. "
02/01/2006 - "Using microRNA (miRNA) array analysis, we report rapid alteration of miRNA levels in response to the potent hydroxamic acid HDACi LAQ824 in the breast cancer cell line SKBr3. "
10/01/2003 - "These findings suggest that LAQ824 is active against human breast cancer cells and has the potential to improve the efficacy of trastuzumab, taxotere, gemcitabine, and epothilone B against breast cancer with Her-2/neuamplification."
10/01/2003 - "Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B."
12/01/2004 - "In addition, we show that NVP-LAQ824 was well tolerated in vivo in a pre-clinical murine leukemia model, with antileukemia activity resulting in significant prolongation of the survival of mice when treated with NVP-LAQ824 compared to control mice. "
04/01/2004 - "Taken together, these findings indicate that LAQ824 may have promising activity in augmenting Apo-2L/TRAIL-induced death-inducing signaling complex and apoptosis of human acute leukemia cells."
01/01/2006 - "Determinants of differentiation and apoptosis induction by the novel histone deacetylase inhibitor (HDACI) LAQ824 were examined in human leukemia cells (U937 and Jurkat). "
12/01/2004 - "The novel histone deacetylase inhibitor NVP-LAQ824: an addition to the therapeutic armamentarium in leukemia?"
08/15/2003 - "Therefore, LAQ824 may be a promising therapeutic agent in the treatment of imatinib-sensitive or -refractory human leukemia."
|4.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
04/01/2004 - "Significantly, cotreatment with LAQ824 increased Apo-2L/TRAIL-induced apoptosis of primary acute myelogenous leukemia blast samples isolated from 10 patients with acute myelogenous leukemia. "
12/01/2004 - "Here we show the activity of NVP-LAQ824 in acute myeloid leukemia cells and BCR/ABL-expressing cells of mouse and human origin, both sensitive and resistant to imatinib mesylate (Gleevec, STI-571). "
11/01/2005 - "Pretreatment (24 hours) with a subtoxic concentration of LAQ824 (30 nmol/L) followed by a minimally toxic concentration of roscovitine (10 micromol/L; 24 hours) resulted in greater than additive effects on apoptosis in U937, Jurkat, and HL-60 human leukemia cells and blasts from three patients with acute myelogenous leukemia. "
08/01/2004 - "Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3."
04/01/2004 - "Present studies demonstrate that treatment with the histone deacetylases inhibitor LAQ824, a cinnamic acid hydroxamate, increased the acetylation of histones H3 and H4, as well as induced p21(WAF1) in the human T-cell acute leukemia Jurkat, B lymphoblast SKW 6.4, and acute myelogenous leukemia HL-60 cells. "
08/01/2006 - "The focus of this study is to elucidate LAQ824 mediated anti-proliferative effects in lung carcinoma cells and the mechanism underlying the different sensitivity of LAQ824 to cancer and normal cells. "
04/01/2008 - "Human HT29 colon carcinoma cells were examined by (31)P MRS after treatment with LAQ824 and another HDAC inhibitor, suberoylanilide hydroxamic acid. "
04/01/2008 - "Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts."
11/01/2006 - "Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2'-deoxycytidine (decitabine) on human breast carcinoma cells."
08/01/2006 - "In HCT116 colon carcinoma xenograft-bearing mice, LAQ824 significantly decreased tumor [18F]FLT uptake in a dose-dependent manner. "
|1.||Histone Deacetylase Inhibitors
|5.||epothilone B (EPO906)
|9.||Hydroxamic Acids (Hydroxamic Acid)
|10.||Histone Deacetylases (Histone Deacetylase)
|1.||Heterologous Transplantation (Xenotransplantation)